These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8968650)

  • 81. Nemonapride for the treatment of schizophrenia.
    Satoh K; Someya T; Shibasaki M
    Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292
    [No Abstract]   [Full Text] [Related]  

  • 82. Guardianship and the right to refuse treatment: a critique of the Roe case.
    Mills MJ; Gutheil TG
    Bull Am Acad Psychiatry Law; 1981; 9(4):239-46. PubMed ID: 6124289
    [No Abstract]   [Full Text] [Related]  

  • 83. Neuroleptic-induced deficit syndrome (NIDS).
    J Clin Psychiatry; 1993 Dec; 54(12):493-500. PubMed ID: 7903967
    [No Abstract]   [Full Text] [Related]  

  • 84. Positive and negative symptoms in schizophrenia: where are the data?
    de Leon J; Simpson GM; Peralta V
    Biol Psychiatry; 1992 Mar; 31(5):431-4. PubMed ID: 1349829
    [No Abstract]   [Full Text] [Related]  

  • 85. Treating negative symptoms.
    Bailey P; Duval F; Macher JP
    Br J Psychiatry; 1994 May; 164(5):699-700. PubMed ID: 7921730
    [No Abstract]   [Full Text] [Related]  

  • 86. The use of dopamine agonists in the treatment of schizophrenia.
    Corsini GU; Pitzalis GF; Bernardi F; Bocchetta A; Del Zompo M
    Neuropharmacology; 1981 Dec; 20(12B):1309-13. PubMed ID: 7033816
    [No Abstract]   [Full Text] [Related]  

  • 87. Psychopharmacologic treatment issues.
    Kane JM
    Psychiatr Med; 1990; 8(1):111-24. PubMed ID: 1974078
    [No Abstract]   [Full Text] [Related]  

  • 88. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.
    Bulut M; Savas HA; Altindag A; Virit O; Dalkilic A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):626-8. PubMed ID: 19735056
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Schizophrenia and antipsychotic medication--better adherence, better outcomes?
    Staring AB; Van der Gaag M; Mulder CL
    Schizophr Res; 2013 Dec; 151(1-3):296-7. PubMed ID: 24238966
    [No Abstract]   [Full Text] [Related]  

  • 90. Drug development and the deficit syndrome of schizophrenia.
    Kirkpatrick B; Carpenter WT
    Biol Psychiatry; 1995 Sep; 38(5):277-8. PubMed ID: 7495920
    [No Abstract]   [Full Text] [Related]  

  • 91. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
    de Millas W; Lambert M; Naber D
    Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Great(er) expectations.
    Lauriello J
    Am J Psychiatry; 2007 Mar; 164(3):377-9. PubMed ID: 17329458
    [No Abstract]   [Full Text] [Related]  

  • 93. Myth and reality of pragmatic trials.
    Mohr P; Bitter I; Constant E; Jakovljević M; Jarema M; Pecenak J; Seifritz E; Svestka J; Sartorius N
    Psychiatr Danub; 2010 Mar; 22(1):2-3. PubMed ID: 20305584
    [No Abstract]   [Full Text] [Related]  

  • 94. Abuse and misuse of anticholinergic medications.
    Land W; Pinsky D; Salzman C
    Hosp Community Psychiatry; 1991 Jun; 42(6):580-1. PubMed ID: 1677920
    [No Abstract]   [Full Text] [Related]  

  • 95. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
    Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
    Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic.
    Pan PC; Tantam D
    Acta Psychiatr Scand; 1989 Jun; 79(6):564-70. PubMed ID: 2569803
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Should the CATIE study be a wake-up call?
    Ragins M
    Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608
    [No Abstract]   [Full Text] [Related]  

  • 98. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia.
    Sirota P; Epstein B; Benatov R; Sousnostzky M; Kindler S
    J Clin Psychopharmacol; 2001 Aug; 21(4):454-5. PubMed ID: 11476132
    [No Abstract]   [Full Text] [Related]  

  • 99. Quality of life of schizophrenic patients on medications and implications for new drug trials.
    Awad AG
    Hosp Community Psychiatry; 1992 Mar; 43(3):262-5. PubMed ID: 1348238
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Recent advances in treatments for schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011; 72 Suppl 1():3. PubMed ID: 22217435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.